Key points are not available for this paper at this time.
- . . 642 6-36 . 1-4 , 1-4 , , SM 7 . 1- 1 6 (129 ); 2- (5% NaF) 2 (123 ); 3- -4 (124 ). 7- 163 . , SM >10 3 , -4- ( Cervite 5-: 4- 4 (52 ), 5- 2 Cervite 2 F- (5% NaF) (51 ). 7- SM 8- - (31 ). ( , -, ). . 1- 1,82 , 2- -0,95, 3- -0,54, 7- -2,50 ( 1-7 =0,18; 2-7 <0,001; 3-7 <0,001). 2- 3- (=0,21). 4- 2,04, 5- -1,35 8- -3,30 ( 4-8 =0,12; 5-8 =0,001). . 2 , 62,0% . 2 2 , 59,1% .
N.V. Shakavets (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: